Iron dextran - PharmaKB

Iron dextran

Ferric Oxyhydroxide, Ferrlecit, Infed, Velphoro, Venofer (iron dextran) is an unknown pharmaceutical. Iron dextran was first approved as Infed on 1982-01-01.

Download report

Favorite

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

Therapeutic Areas

No data

Trade Name

FDA

EMA

Infed (discontinued: Dexferrum, Iron dextran, Proferdex)

Drug Products

FDA

EMA

New Drug Application (NDA)

Abbreviated New Drug Application (ANDA)

Iron dextran

Tradename	Company	Number	Date	Products
INFED	Allergan	N-017441 RX	1982-01-01	1 products, RLD, RS

Show 3 discontinued

Labels

FDA

EMA

Brand Name	Status	Last Update
infed	New Drug Application	2026-04-15
iron dextran	New Drug Application	2025-01-08
venofer	New Drug Application	2026-03-01
venofer (iron sucrose)	New Drug Application	2024-04-19

Indications

FDA

EMA

No data

Agency Specific

FDA

EMA

No data

Patent Expiration

Patent	Expires	Flag	FDA Information
Ferric Oxyhydroxide, Velphoro, Vifor Fresenius
10624855	2034-11-26	DP
11234938	2034-11-26	DP
11446252	2034-11-26	DP
9561251	2030-01-23	DP	U-1468
10682376	2028-11-13	DP
10695367	2028-11-13	DP
10925896	2028-11-13	DP
10925897	2028-11-13	DP
10933090	2028-11-13	DP
11013761	2028-11-13	DP
11013762	2028-11-13	DP

ATC Codes

No data

HCPCS

Code	Description
J1750	Injection, iron dextran, 50 mg

Clinical

Clinical Trials

2487 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Iron deficiencies	D000090463	—	E61.1	29	51	104	129	416	715
Anemia	D000740	EFO_0004272	D64.9	37	73	138	138	312	680
Iron-deficiency anemia	D018798	—	D50	29	50	111	117	360	653
Iron overload	D019190	—	—	10	47	17	21	69	156
Deficiency diseases	D003677	EFO_1001067	E63	9	7	35	18	45	112
Chronic renal insufficiency	D051436	—	N18	9	11	37	27	20	102
Kidney diseases	D007674	EFO_0003086	N08	7	11	32	22	26	96
Thalassemia	D013789	EFO_1001996	D56	10	27	10	13	38	89
Heart failure	D006333	EFO_0003144	I50	3	4	15	30	18	67
Beta-thalassemia	D017086	Orphanet_848	D56.1	7	23	10	10	25	67

Show 199 more

Indications Phases 3

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Growth disorders	D006130	—	—	—	—	2	—	19	21
Diabetes mellitus	D003920	EFO_0000400	E08-E13	1	4	2	—	11	17
Leukemia	D007938	—	C95	2	6	3	—	7	16
Child development	D002657	—	—	—	—	2	—	13	15
Liver diseases	D008107	EFO_0001421	K70-K77	1	2	1	—	10	14
Parkinson disease	D010300	EFO_0002508	G20	2	4	1	—	9	14
Fatty liver	D005234	EFO_0003934	—	1	3	2	—	9	13
Liver cirrhosis	D008103	EFO_0001422	K74.0	—	—	2	—	10	12
Blood transfusion	D001803	—	—	—	1	1	—	10	11
Non-alcoholic fatty liver disease	D065626	EFO_0003095	K75.81	1	3	2	—	6	10

Show 108 more

Indications Phases 2

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Metabolic diseases	D008659	EFO_0000589	E88.9	1	1	—	—	13	15
Brain neoplasms	D001932	EFO_0003833	C71	7	5	—	—	1	13
Cognitive dysfunction	D060825	—	G31.84	1	2	—	—	7	10
Myeloid leukemia acute	D015470	—	C92.0	1	5	—	—	4	9
Hereditary hemorrhagic telangiectasia	D013683	—	I78.0	1	2	—	—	5	8
Metabolic syndrome	D024821	EFO_0000195	E88.810	—	1	—	—	7	8
Glioblastoma	D005909	EFO_0000515	—	3	1	—	—	4	8
Neurodegenerative diseases	D019636	EFO_0005772	G31.9	1	1	—	—	6	8
Replacement arthroplasty knee	D019645	—	—	—	1	—	—	6	7
Insulin resistance	D007333	EFO_0002614	E88.819	1	1	—	—	5	7

Show 150 more

Indications Phases 1

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Obesity	D009765	EFO_0001073	E66.9	2	—	—	—	31	33
Hookworm infections	D006725	EFO_0007314	B76	6	—	—	—	2	8
Lung neoplasms	D008175	—	C34.90	1	—	—	—	6	7
Ancylostomiasis	D000724	EFO_0007145	B76.0	6	—	—	—	1	7
Vasodilation	D014664	—	—	3	—	—	—	3	6
Body weight	D001835	EFO_0004338	—	1	—	—	—	5	6
Folic acid deficiency	D005494	EFO_0001070	E53.8	1	—	—	—	5	6
Vasoconstriction	D014661	—	—	3	—	—	—	2	5
Aging	D000375	GO_0007568	R41.81	2	—	—	—	3	5
Hepatic insufficiency	D048550	—	—	2	—	—	—	2	4

Show 50 more

Indications Without Phase

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Hypersensitivity	D006967	EFO_0003785	T78.40	—	—	—	—	8	8
Nutrition disorders	D009748	EFO_0001069	—	—	—	—	—	7	7
Breast feeding	D001942	—	—	—	—	—	—	7	7
Nutritional status	D009752	—	—	—	—	—	—	7	7
Vitamin b 12 deficiency	D014806	EFO_0000734	E53.8	—	—	—	—	6	6
Pre-eclampsia	D011225	EFO_0000668	O14	—	—	—	—	6	6
Motor activity	D009043	EFO_0003940	—	—	—	—	—	6	6
Gestational weight gain	D000078064	—	—	—	—	—	—	5	5
Exercise	D015444	EFO_0000483	—	—	—	—	—	4	4
Respiratory tract infections	D012141	—	J06.9	—	—	—	—	4	4

Show 415 more

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	Iron dextran
INN	_
Description	Iron supplements, also known as iron salts and iron pills, are a number of iron formulations used to treat and prevent iron deficiency including iron deficiency anemia. For prevention they are only recommended in those with poor absorption, heavy menstrual periods, pregnancy, hemodialysis, or a diet low in iron. Prevention may also be used in low birth weight babies. They are taken by mouth, injection into a vein, or injection into a muscle. While benefits may be seen in days, up to two months may be required until iron levels return to normal.
Classification	Small molecule
Drug class	—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	—